Thrombotic Microangiopathy, Cancer, and Cancer Drugs

American Journal of Kidney Diseases

Volumn 66, Issue 5, 2015, Pages 857-868

  Izzedine, Hassan ^a   Perazella, Mark A ^b  

^a Monceau Park International Clinic   (France)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACDIT; anti VEGF; chemotherapy; DIC; disseminated intravascular coagulopathy; drug induced TMA; onco nephrology; review; Thrombotic microangiopathy

Indexed keywords

CALCIUM; CAPECITABINE; CELECOXIB; CREATININE; GEMCITABINE; LISINOPRIL; MULTIVITAMIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DEOXYCYTIDINE; IMMUNOSUPPRESSIVE AGENT; VASCULOTROPIN A;

AGED; ANEMIA; ARTICLE; ASCITES; BORDERLINE HYPERTENSION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CREATININE BLOOD LEVEL; ELEVATED BLOOD PRESSURE; EPISTAXIS; ERYTHROCYTE; FATIGUE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KNEE OSTEOARTHRITIS; LABORATORY TEST; LEG EDEMA; LEUKOCYTE; LIVER METASTASIS; MALE; MEDICAL HISTORY; METASTASIS; MICROSCOPY; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; PALLOR; PANCREAS CANCER; PERITONEUM METASTASIS; PHYSICAL EXAMINATION; PURPURA; SKIN DEFECT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; KIDNEY; NEOPLASMS; PANCREATIC NEOPLASMS; PATHOLOGY; PLASMAPHERESIS; PROCEDURES; THROMBOTIC MICROANGIOPATHIES;

ADRENAL CORTEX HORMONES; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PLASMAPHERESIS; THROMBOTIC MICROANGIOPATHIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84945437213     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.02.340     Document Type: Article

References (134)

1. R. Pisoni, P. Ruggenenti, and G. Remuzzi Drug-induced thrombotic microangiopathy; incidence, prevention, and management Drug Saf 24 2001 491 501
2. T.C. Nguyen, and J.A. Carcillo Bench-to-bedside review: thrombocytopenia-associated multiple organ failure: a newly appreciated syndrome in the critically ill Crit Care 10 2006 235 242
3. H.C. Kwaan Miscellaneous secondary thrombotic microangiopathy Semin Hematol 24 1987 141 147
4. W.T. Hanna, S. Krauss, R.F. Regester, and et al. Renal disease after mitomycin C therapy Cancer 48 1981 2583 2588
5. J.J. Byrnes, H. Baquerizo, M. Gonzalez, and G.T. Hensely Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy Am J Hematol 21 1986 299 304
6. J.B. Lesesne, N. Rothschild, B. Erickson, and et al. Cancer-associated hemolytic uremic syndrome: analysis of 85 cases from a national registry J Clin Oncol 7 1989 781 789
7. H. Izzedine, B. Escudier, L. Lhomme, and et al. Anti-VEGF associated kidney diseases: an 8-year monocentric observational study Medicine (Baltimore) 93 2014 333 339
8. D.C. Doll, Q.S. Ringenberg, and J.W. Yarbro Vascular toxicity associated with antineoplastic agents J Clin Oncol 4 1986 1405 1417
9. W.C. Symmers Thrombotic microangiopathic haemolytic anemia Br Med J 2 1952 897 903
10. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 Published May 28, 2009 (v4.03: June 14, 2010). US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed November 3, 2014.
11. G.G. Levy, W.C. Nichols, E.C. Lian, and et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura Nature 413 2001 488 494
12. M. Malina, L.T. Roumenina, T. Seeman, and et al. Genetics of hemolytic uremic syndromes Presse Med 41 2012 e105 e114
13. P. Warwicker, T.H. Goodship, R.L. Donne, and et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome Kidney Int 53 1998 836 844
14. A. Richards, E.J. Kemp, M.K. Liszewski, and et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome Proc Natl Acad Sci U S A 100 2003 12966 12971
15. V. Fremeaux-Bacchi, M.A. Dragon-Durey, J. Blouin, and et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome J Med Genet 41 2004 e84 e88
16. J. Monteagudo, A. Pereira, S. Roig, and et al. Investigation of plasma von Willebrand factor and circulating platelet aggregating activity in mitomycin C-related hemolytic-uremic syndrome Am J Hematol 33 1990 46 49
17. D. Charba, J.L. Moake, M.A. Harris, and J.P. Hester Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies Am J Hematol 42 1993 268 277
18. H. Izzedine, M. Mangier, V. Ory, and et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy Kidney Int 85 2014 457 470
19. V. Eremina, J.A. Jefferson, J. Kowalewska, and et al. VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 2008 1129 1136
20. J.E. Cantrell Jr., T.M. Phillips, and P.S. Schein Carcinoma-associated hemolytic-uremic syndrome. A complication of mitomycin C chemotherapy J Clin Oncol 3 1985 723 734
21. R. Sheldon, and D. Slaughter A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma Cancer 58 1986 1428 1436
22. K. Lechner, and H.L. Obermeier Cancer-related microangiopathic hemolytic anemia Medicine (Baltimore) 91 2012 195 205
23. A.J. Murgo Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents Semin Hematol 24 1987 161 177
24. D.L. Laffay, R.R. Tubbs, R. Valenzuela, and et al. Chronic glomerular microangiopathy and metastatic carcinoma Hum Pathol 10 1979 433 438
25. J.C. Chang, and T. Naqvi Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer Oncologist 8 2003 375 380
26. K.K. Francis, N. Kalyanam, D.R. Terrell, and et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases Oncologist 12 2007 11 19
27. T.L. Werner, N. Agarwal, H.M. Carney, and G.M. Rodgers Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol 82 2007 295 298
28. J.N. George Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia Oncology (Williston Park) 25 2011 908 914
29. C. Robier, M. Neubauer, C. Beham-Schmid, and H. Sill Thrombotic microangiopathy and disseminated intravascular coagulation associated with carcinocythemia in a patient with breast cancer J Clin Oncol 29 2011 e825 e826
30. R.W. Colman, and R.N. Rubin Disseminated intravascular coagulation due to malignancy Semin Oncol 17 1990 172 186
31. Y. Chang, R. Hsieh, M. Chang, and et al. Breast cancer with an unusual leukemia-like presentation: case report and literature review Med Oncol 25 2008 100 103
32. V. Pitini, C. Arrigo, and G. Altavilla An acute-leukemia-like picture due to breast carcinoma cells Lancet Oncol 7 2006 524
33. M.C. Brain, J.G. Azzopardi, L.R. Baker, and et al. Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma Br J Haematol 18 1970 183 193
34. L. Oleksowicz, N. Bhagwati, and M. DeLeon-Fernandez Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies Cancer Res 59 1999 2244 2250
35. P.M. Mannucci, M. Karimi, A. Mosalaei, and et al. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease) Haematologica 88 2003 454 458
36. S. Fontana, H.E. Gerritsen, J. Kremer Hovinga, and et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease Br J Haematol 113 2001 100 102
37. B.L. Laskin, J. Goebel, S.M. Davies, and S. Jodele Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy Blood 118 2011 1452 1462
38. K. Siami, K. Kojouri, K.K. Swisher, and et al. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study Transplantation 85 2008 22 28
39. S. Changsirikulchai, D. Myerson, K.A. Guthrie, G.B. McDonald, C.E. Alpers, and S.R. Hingorani Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis Clin J Am Soc Nephrol 4 2009 345 353
40. P. Iacopino, G. Pucci, W. Arcese, and et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation Bone Marrow Transplant 24 1999 47 51
41. V. Roy, M.A. Rizvi, S.K. Vesely, and J.N. George Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes Bone Marrow Transplant 27 2001 641 646
42. J.N. George, X. Li, J.R. McMinn, and et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma Transfusion 44 2004 294 304
43. C.R. Parikh, and S.G. Coca Acute renal failure in hematopoietic cell transplantation Kidney Int 69 2006 430 435
44. M.H. Griffiths, A.V. Crowe, L. Papadaki, and et al. Cyclosporin nephrotoxicity in heart and lung transplant patients QJM 89 1996 751 763
45. J.N. George The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007 Kidney Int Suppl 112 2009 S52 S54
46. J.N. George, S.K. Vesely, D.R. Terrell, and et al. The Oklahoma Thrombotic Thrombocytopenic Purpura-Haemolytic Uraemic Syndrome Registry. A model for clinical research, education and patient care Hamostaseologie 33 2013 105 112
47. S. Serke, H. Riess, H. Oettle, and D. Huhn Elevated reticulocyte count: a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report Br J Cancer 79 1999 1519 1521
48. C. Gasser, E. Gautier, A. Steck, and et al. Hemolyticuremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia Schweiz Med Wochenschr 85 1955 905 909
49. M.W. Saif, and P.J. McGee Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature JOP 6 2005 369 374
50. T.J. Raife, and D.J. Lager Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects Mayo Clin Proc 77 2002 323 358
51. J.S. Dlott, C.F. Danielson, D.E. Blue-Hnidy, and L.J. McCarthy Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review Ther Apher Dial 8 2004 102 111
52. L. Shavit, M.D. Lifschitz, A. Gabizon, M. Kwa, F. Muggia, and I. Slotki Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer Kidney Int 85 2014 211 216
53. C.P.P. Canoplat, and N. Jaffe Cisplatin-associated hemolytic uremic syndrome Cancer 74 1994 3059 3062
54. T.M. Price, A.J. Murgo, J.J. Keveney, and et al. Renal failure and hemolytic anemia associated with mitomycin C. A case report Cancer 55 1985 51 56
55. E. Poch, J.M. González-Clemente, A. Torras, and et al. Silent renal microangiography after mitomycin C therapy Am J Nephrol 10 1990 514 517
56. J.A. Groff, M. Kozak, J.P. Boehmer, and et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy Am J Kidney Dis 29 1997 280 284
57. A.M. Jackson, B.D. Rose, L.G. Graff, and et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy Ann Intern Med 101 1984 41 44
58. R. Valavaara, and E. Nordman Renal complications of mitomycin C therapy with special reference to the total dose Cancer 55 1985 47 50
59. H. Izzedine, I. Brocheriou, G. Deray, and O. Rixe Thrombotic microangiopathy and anti-VEGF agents Nephrol Dial Transplant 22 2007 1481 1482
60. R.B. Walter, M. Joerger, and B.C. Pestalozzi Gemcitabine-associated hemolytic-uremic syndrome Am J Kidney Dis 40 2002 E16 E21
61. M. Zupancic, P.C. Shah, and F. Shah-Khan Gemcitabine associated thrombotic thrombocytopenic purpura Lancet Oncol 8 2007 634 641
62. C.D. Flombaum, J.A. Mouradian, E.S. Casper, R.A. Erlandson, and F. Benedetti Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine Am J Kidney Dis 33 3 1999 555 562
63. I. Glezerman, M.G. Kris, V. Miller, and et al. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution Clin Nephrol 71 2009 130 139
64. B.D. Humphreys, J.P. Sharman, J.M. Henderson, and et al. Gemcitabine associated thrombotic microangiopathy Cancer 100 2004 2664 2670
65. M.C. Fung, A.M. Storniolo, B. Nguyen, M. Arning, W. BrookWeld, and J. Vigil A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy Cancer 85 1999 2023 2032
66. H. Izzedine, V. Launay-Vacher, L. Mercadal, and et al. Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy Am J Hematol 77 2004 319
67. J.T. Licciardello, J.L. Moake, C.K. Rudy, D.D. Karp, and W.K. Hong Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy Oncology 42 1985 296 300
68. T. Khansur, and A. Kennedy Case report: cisplatin-induced hemolytic uremic syndrome Am J Med Sci 301 1991 390 392
69. G. Gardner, D. Mesler, and H.J. Gitelman Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy. A report of a case and a review of the literature Ren Fail 11 1989 133 137
70. J. Van der Meer, E.G.E. de Vries, R. Vriesendorp, P.H.B. Williemse, A.J.M. Donker, and J.G. Aalders Hemolytic uremic syndrome in a patient on cis-platinum, vinblastine and bleomycin Cancer Res Clin Oncol 110 1985 119 122
71. W.J. Gradishar, E.E. Vokes, K. Ni, and W.R. Panje Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report Cancer 66 1990 1914 1918
72. C. Porta, M. Danova, A. Riccardi, E. Bobbio-Pallavicini, and E. Ascari Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production Mayo Clin Proc 74 1999 570 574
73. D. Thurnher, J. Kletzmayr, M. Formanek, and et al. Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx Oncology 61 2001 143 146
74. J. Palmisano, M. Agraharkar, and A.A. Kaplan Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange Am J Kidney Dis 32 1998 314 317
75. G. Rabinowits, D. Herchenhorn, M. Rabinowits, D. Weatge, and W. Torres Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine Anticancer Drugs 14 2003 665-658
76. R.W. Walker, M.K. Rosenblum, S.J. Kempin, and M.C. Christian Carboplatin-associated thrombotic microangiopathic hemolytic anemia Cancer 64 1989 1017 1020
77. M. Gross, C. Hiesse, F. Kriaa, and F. Goldwasser Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine Anticancer Drugs 10 1999 533 536
78. S. Rodenhuis, A. Westermann, M.J. Holtkamp, and et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer J Clin Oncol 14 1996 1473 1483
79. W. Lams, K.E. Beckermann, A.T. Neff, I.A. Mayer, and V.G. Abramson Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report Med Oncol 30 2013 568 572
80. M.W. Saif, A. The, and L. Ledbetter Oxaliplatin-mediated autoimmune thrombocytopenia Clin Colorectal Cancer 8 2009 61 62
81. M.A. Bautista, W.T. Stevens, C.S. Chen, B.R. Curtis, R.H. Aster, and C.T. Hsueh Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature J Hematol Oncol 3 2010 12 19
82. J. Niu, and M.P. Mims Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review J Clin Oncol 30 2012 312 314
83. P. Racca, R. Spadi, G. Fora, and et al. Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report Tumori 97 2011 31e 33e
84. I. Dahabreh, G. Tsoutsos, D. Tseligas, and D. Janinis Hemolytic uremic syndrome following the infusion of oxaliplatin: case report BMC Clin Pharmacol 6 2006 5
85. F.M. Muggia, J.D. Hainsworth, S. Jeffers, and et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 1997 987 993
86. M. Kwa, R. Baumgartner, L. Shavit, and et al. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Oncologist 17 2012 1534 1540
87. J.A. Blake-Haskins, R.J. Lechleider, and R.J. Kreitman Thrombotic microangiopathy with targeted cancer agents Clin Cancer Res 17 2011 5858 5866
88. R.J. Kreitman, D.R. Squires, M. Stetler-Stevenson, and et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies J Clin Oncol 23 2005 6719 6729
89. R.J. Kreitman, W.H. Wilson, K. Bergeron, and et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia N Engl J Med 345 2001 241 247
90. R.J. Kreitman, M. Stetler-Stevenson, I. Margulies, and et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia J Clin Oncol 27 2009 2983 2990
91. R.J. Kreitman, M.S. Tallman, S. Coutre, and et al. Phase I dose-escalation study of CAT-8015 (HA22), a CD22-specific targeted immunotoxin, in relapsed or refractory hairy cell leukemia [abstract 888] Blood 2009 (ASH Annual Meeting Abstracts):114
92. R.A. Messmann, E.S. Vitetta, D. Headlee, and et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma Clin Cancer Res 6 2000 1302 1313
93. C.F. LeMaistre, F.E. Craig, C. Meneghetti, and et al. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers Cancer Res 53 1993 3930 3934
94. F.M. Foss, T.A. Borkowski, M. Gilliom, and et al. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study Blood 84 1994 1765 1774
95. T.S. Lin, W. Stock, H. Xu, and et al. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia Leuk Lymphoma 50 2009 1958 1963
96. K. Dunleavy, T. White, N. Grant, and et al. Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia J Clin Oncol 23 suppl 16S 2005 6607
97. J.D. Isaacs, V.K. Manna, N. Rapson, and et al. CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study Br J Rheumatol 35 1996 231 240
98. C. Frangie, C. Lefaucheur, J. Medioni, C. Jacquot, G. Hill, and D. Nochy Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma Lancet Oncol 8 2007 177 178
99. E. Kapiteijn, A. Brand, J. Kroep, and H. Gelderblom Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome Ann Oncol 18 2007 1745 1747
100. G. Bollee, N. Patey, G. Cazajous, and et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib Nephrol Dial Transplant 24 2009 682 685
101. D.R. Feldman, M.S. Baum, M.S. Ginsberg, and et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1432 1439
102. Z. Al Aly, J.M. Philocet Ashley, M.E. Gellens, and E. Gonzalez Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence? Am J Kidney Dis 45 2005 762 768
103. E.S. den Deurwaarder, I.M. Desar, E.J. Steenbergen, P.F. Mulders, J.F. Wetzels, and C.M. van Herpen Kidney injury during VEGF inhibitor therapy Neth J Med 70 2012 267 271
104. C. Vigneau, N. Lorcy, T. Dolley-Hitze, and et al. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study Nephrol Dial Transplant 29 2014 325 332
105. J.C. Soria, F. DeBraud, R. Bahleda, and et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors Ann Oncol 25 2014 2244 2251
106. M.K. Choi, J.Y. Hong, J.H. Jang, and H.Y. Lim TTP-HUS associated with sunitinib Cancer Res Treat 40 2008 211 213
107. T.N. Talebi, A. Stefanovic, J. Merchan, and et al. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome Am J Ther 19 2012 e143 e145
108. R. Jain, P. Mathew, C.G. Wood, and N.M. Tannir Sunitinib-induced acute hemolysis without hypertension: a case report Clin Genitourin Cancer 6 2008 122 123
109. A.J. Murgo Cancer- and chemotherapy-associated thrombotic microangiopathy B.S. Kaplan, R.S. Trompeter, J.L. Moake, Hemolytic-Uremic Syndrome and Thrombotic Thrombocytopenic Purpura Vol. 22 1992 Marcel Dekker Ltd New York, NY 271 295
110. H.W. Snyder Jr., A. Mittelman, A. Oral, and et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma Cancer 71 1993 1882 1892
111. K. Siau, and M. Varughese Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report Med Oncol 27 2010 1057 1059
112. J. Nurnberger, T. Philipp, O. Witzke, and et al. Eculizumab for atypical hemolytic-uremic syndrome N Engl J Med 360 2009 542 544
113. R. Gruppo, and R. Rother Eculizumab for congenital atypical hemolytic-uremic syndrome N Engl J Med 360 2009 544 546
114. J. de la Rubia, F. Moscardo, M. Gomez, and et al. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study Transfus Apher Sci 43 2010 299 303
115. F. Fakhouri, L. Teixeira, R. Delarue, J.P. Grunfeld, and A. Veyradier Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide Ann Intern Med 140 2004 314 315
116. M. Galbusera, E. Bresin, M. Noris, and et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report Blood 106 2005 925 928
117. H. Kaneko, M. Matsumoto, K. Okamoto, and et al. Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine Rinsho Ketsueki 48 2007 144 147
118. F. Fakhouri, J.P. Vernant, A. Veyradier, and et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases Blood 106 2005 1932 1937
119. S.K. Yassa, G. Blessios, G. Marinides, and R.C. Venuto Anti-CD20 monoclonal antibody (rituximab) for life-threatening hemolytic-uremic syndrome Clin Transpl 19 2005 423 426
120. M. OstronoV, F. OstronoV, R. Calixto, and et al. Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient Bone Marrow Transplant 39 2007 649 651
121. S. Kasper, M.F. Neurath, C. Huber, M. Theobald, and I. Scharrer Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy Transfusion 47 2007 1263 1267
122. A. Bharthuar, L. EgloV, J. Becker, and et al. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report Cancer Chemother Pharmacol 64 2009 177 181
123. A.A. Onitilo, J.M. Engel, L.H. Clouse, and K.M. Gerndt Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab Vasc Interv Radiol 20 2009 275 276
124. C. Orvain, J.F. Augusto, V. Besson, and et al. Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis Int Urol Nephrol 46 2014 239 242
125. J. Mahe, A. Meurette, A. Moreau, C. Vercel, and P. Jolliet Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis Drug Des Devel Ther 7 2013 723 738
126. M. Starck, and C.M. Wendtner Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy Br J Haematol 164 2014 888 902
127. S. Jodele, T. Fukuda, A. Vinks, and et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy Biol Blood Marrow Transplant 20 2014 518 525
128. S. Jodele, C. Licht, J. Goebel, and et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy Blood 122 2013 2003 2007
129. S. Jodele, S.M. Davies, A. Lane, and et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults Blood 124 2014 645 653
130. H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa, and R. Ohno Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: result of a phase III, randomized, double-blind clinical trial J Thromb Haemost 5 2007 31 41
131. M. Sakai, T. Ikezoe, K. Bandobashi, K. Togitani, and A. Yokoyama Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin Bone Marrow Transplant 45 2010 803 805
132. M. Sakai, T. Ikezoe, K. Bandobashi, and A. Yokoyama Successful treatment of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with recombinant human soluble thrombomodulin Thromb Res 126 2010 e392 e393
133. Y. Nishijima, H. Hirata, A. Himeno, and et al. Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin Intern Med 52 2013 1111 1114
134. E.M. Conway Thrombomodulin and its role in inflammation Semin Immunopathol 34 2012 107 125